Tuesday , April 24 2018
Home / Therapies / GLP-1 Agonist Therapy Center (page 10)

GLP-1 Agonist Therapy Center

GLP-1 Diabetes Drug Treatment: GLP-1 (glucagon-like peptide 1 receptor agonists) are incretin mimetics which have several benefits for diabetes management. They suppress post-prandial glucagon release, delay stomach emptying, and increase insulin sensitivity. Significantly lower rates of hypoglycemia accompany GLP-1 therapy. This class also has the side effect of modest weight reduction and reduction of systolic blood pressure. GLP-1 receptor agonists are counter-indicated for patients with a history of pancreatitis.

GLP-1 Serum Levels Associated with Coronary Artherosclerosis

Prior reports of GLP-1 vasoprotective effects may not be valid…. Prior reports have shown that GLP-1 concentrations are associated with anti-inflammatory and atheroprotective effects which extend to cardioprotection during acute myocardial infarction. In the body, GLP-1 binds to its receptors on pancreatic beta-cells leading to glucose dependent insulin release. Studies …

Read More »

IV Versus SubQ for GLP-1 Drugs

How to unlock GLP-1 drugs’ full glucose-lowering potential…. The current subcutaneous delivery method of GLP-1 agonist drugs for patients with type 2 diabetes may not be the most effective. According to Michael Nauchk, MD, intravenously administered infusions of GLP-1 resulted in normalization of blood glucose without gastrointestinal upset, while subcutaneous …

Read More »

Positive Results for Next Once A Week GLP-1

Five studies show positive results for new GLP-1 drug dulaglutide…. Eli Lilly and Company announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes. Primary efficacy endpoints of …

Read More »